Your browser doesn't support javascript.
loading
Pt-Mal-LHRH, a Newly Synthesized Compound Attenuating Breast Cancer Tumor Growth and Metastasis by Targeting Overexpression of the LHRH Receptor.
Calderon, Lindsay E; Keeling, Jonathan K; Rollins, Joseph; Black, Carrie A; Collins, Kendall; Arnold, Nova; Vance, Diane E; Ndinguri, Margaret W.
Afiliación
  • Calderon LE; Department of Biology, Eastern Kentucky University , Richmond, Kentucky 40475, United States.
  • Keeling JK; Department of Chemistry, Eastern Kentucky University , Richmond, Kentucky 40475, United States.
  • Rollins J; Department of Biology, Eastern Kentucky University , Richmond, Kentucky 40475, United States.
  • Black CA; Department of Chemistry, Eastern Kentucky University , Richmond, Kentucky 40475, United States.
  • Collins K; Department of Biology, Eastern Kentucky University , Richmond, Kentucky 40475, United States.
  • Arnold N; Department of Biology, Eastern Kentucky University , Richmond, Kentucky 40475, United States.
  • Vance DE; Department of Chemistry, Eastern Kentucky University , Richmond, Kentucky 40475, United States.
  • Ndinguri MW; Department of Chemistry, Eastern Kentucky University , Richmond, Kentucky 40475, United States.
Bioconjug Chem ; 28(2): 461-470, 2017 Feb 15.
Article en En | MEDLINE | ID: mdl-27997127
ABSTRACT
A new targeting chemotherapeutic agent, Pt-Mal-LHRH, was synthesized by linking activated cisplatin to luteinizing hormone releasing hormone (LHRH). The compound's efficacy and selectivity toward 4T1 breast cancer cells were evaluated. Carboplatin was selected as the comparative platinum complex, since the Pt-Mal-LHRH malonate linker chelates platinum in a similar manner to carboplatin. Breast cancer and normal cell viability were analyzed by an MTT assay comparing Pt-Mal-LHRH with carboplatin. Cells were also treated with either Pt-Mal-LHRH or carboplatin to evaluate platinum uptake by ICP-MS and cell migration using an in vitro scratch-migration assay. Tumor volume and metastasis were evaluated using an in vivo 4T1 mouse tumor model. Mice were administered Pt-Mal-LHRH (carboplatin molar equivalent dosage) through ip injection and compared to those treated with carboplatin (5 (mg/kg)/week), no treatment, and LHRH plus carboplatin (unbound) controls. An MTT assay showed a reduction in cell viability (p < 0.01) in 4T1 and MDA-MB-231 breast cancer cells treated with Pt-Mal-LHRH compared to carboplatin. Pt-Mal-LHRH was confirmed to be cytotoxic by flow cytometry using a propidium iodide stain. Pt-Mal-LHRH displayed a 20-fold increase in 4T1 cellular uptake compared to carboplatin. There was a decrease (p < 0.0001) in 4T1 cell viability compared to 3T3 normal fibroblast cells. Treatment with Pt-Mal-LHRH also resulted in a significant decrease in cell-migration compared to carboplatin. In vivo testing found a significant reduction in tumor volume (p < 0.05) and metastatic tumor colonization in the lungs with Pt-Mal-LHRH compared to carboplatin. There was a slight decrease in lung weight and no difference in liver weight between treatment groups. Together, our data indicate that Pt-Mal-LHRH is a more potent and selective chemotherapeutic agent than untargeted carboplatin.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mama / Neoplasias de la Mama / Hormona Liberadora de Gonadotropina / Cisplatino / Sistemas de Liberación de Medicamentos / Receptores LHRH / Antineoplásicos Límite: Animals / Female / Humans Idioma: En Revista: Bioconjug Chem Asunto de la revista: BIOQUIMICA Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mama / Neoplasias de la Mama / Hormona Liberadora de Gonadotropina / Cisplatino / Sistemas de Liberación de Medicamentos / Receptores LHRH / Antineoplásicos Límite: Animals / Female / Humans Idioma: En Revista: Bioconjug Chem Asunto de la revista: BIOQUIMICA Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos